The dispute between Bayer Yakuhin, the originator company for the Eylea biosimilar, and the follow-on companies continues, with proceedings advancing over an injunction against its manufacture and sale in Japan. The Ministry of Health, Labour and Welfare will pilot an expert committee system to verify patent infringement.
The dispute between originator company Bayer Yakuhin and several follow-on companies over a biosimilar of Eylea, an ophthalmic anti-VEGF fusion protein, continues.
In November 2025, Bayer Yakuhin sought an injunction against Fuji Pharma's manufacture and sale of aflibercept BS in Japan.
Fuji Pharma has stated that its product does not infringe any patent rights, putting the positions of the two companies at odds.
The Ministry of Health, Labour and Welfare plans to pilot an expert committee system to verify whether generic and other follow-on products infringe patents.